WALKER WAYNE REMELL

SEC source: 0001428761-26-000003 · primarydocument.xml · derivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,601 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each unit represents a contingent right to receive one share of Pitney Bowes common stock.

F2 · derivative.exercise_date: Restricted Stock Units granted to non-employee directors on September 22, 2025 cliff vested according to schedule on September 22, 2026.

F2 · derivative.expiration_date: Restricted Stock Units granted to non-employee directors on September 22, 2025 cliff vested according to schedule on September 22, 2026.

SEC source: 0001428761-26-000003 · primarydocument.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-356101 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 191,413

F1 · price: Reflects the grant of 15,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service. The reporting person pays no consideration for these shares.

SEC source: 0001493152-26-029423 · ownership.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,042

Underlying: Common Stock · 45,042 shares

Expires 2036-06-18

F1 · derivative.exercise_date: The stock options vest as follows: (i) 25% vested upon the date of grant; (ii) 25% will vest on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026, provided that the Reporting Person remains employed by or providing services to the Issuer on the applicable vesting date.

SEC source: 0001104659-26-071436 · tm2617013-1_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 881,333

F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

SEC source: 0001428761-26-000002 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,413

F1 · price: Reflects the grant of 15,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001428761-26-000001 · primarydocument.xml · derivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,292

Underlying: Common Stock · 18,159 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents a contingent right to receive one share of Pitney Bowes common stock.

F2 · derivative.exercise_date: The Restricted Stock Units granted May 12, 2026 will cliff vest after one year.

F2 · derivative.expiration_date: The Restricted Stock Units granted May 12, 2026 will cliff vest after one year.

SEC source: 0001428761-26-000001 · primarydocument.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,133

Underlying: Common Stock · 6,532 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents a contingent right to receive one share of Pitney Bowes common stock.

F2 · derivative.exercise_date: The Restricted Stock Units granted May 12, 2026 will cliff vest after one year.

F2 · derivative.expiration_date: The Restricted Stock Units granted May 12, 2026 will cliff vest after one year.

SEC source: 0001683168-26-002632 · ownership.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,170

Underlying: Common Stock · 119,170 shares

Expires 2036-03-30

F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker.

SEC source: 0001683168-26-005622 · ownership.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

F1 · security: The reported grant was made in error and has been cancelled.

F1 · derivative.exercise_price: The reported grant was made in error and has been cancelled.

F1 · date: The reported grant was made in error and has been cancelled.

F1 · kind: The reported grant was made in error and has been cancelled.

F1 · shares: The reported grant was made in error and has been cancelled.

F1 · price: The reported grant was made in error and has been cancelled.

F1 · derivative.exercise_date: The reported grant was made in error and has been cancelled.

F1 · derivative.expiration_date: The reported grant was made in error and has been cancelled.

F1 · derivative.underlying: The reported grant was made in error and has been cancelled.

F1 · derivative.underlying_shares: The reported grant was made in error and has been cancelled.

F1 · balance_after: The reported grant was made in error and has been cancelled.

SEC source: 0001193125-26-057043 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,413

F1 · price: Reflects the grant of 15,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001104659-26-000237 · tm261718-3_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 506,333

F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer.

F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025.

SEC source: 0001683168-25-009115 · ownership.xml · nonDerivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,625

F1 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

SEC source: 0001683168-25-009115 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

SEC source: 0001193125-25-286404 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,413

F1 · price: Reflects the grant of 15,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001493152-25-020433 · ownership.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,723

Underlying: Common Stock · 22,723 shares

Expires 2035-10-31

F1 · derivative.exercise_date: The stock options vest as follows: (i) 75% vested upon the date of grant; and (ii) 25% will vest on December 31, 2025, provided that the Reporting Person remains employed by or providing services to the Issuer on the applicable vesting date.

SEC source: 0001428761-25-000006 · primarydocument.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,601

Underlying: Common Stock · 5,601 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents a contingent right to receive one share of Pitney Bowes common stock.

F2 · derivative.exercise_date: The Restricted Stock Units granted September 22, 2025 are scheduled to cliff vest one year after the date of grant.

F2 · derivative.expiration_date: The Restricted Stock Units granted September 22, 2025 are scheduled to cliff vest one year after the date of grant.

SEC source: 0000950170-25-093115 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,413

SEC source: 0001683168-25-009115 · ownership.xml · derivative · entry 3

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,233

Underlying: Common Stock · 63,233 shares

Expires 2035-04-24

F2 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker.

SEC source: 0001641172-25-002454 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,413

F1 · price: Reflects the grant of 15,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001104659-25-016203 · tm257316-5_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,314

F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date.

SEC source: 0001493152-25-002187 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,413

F1 · price: Reflects the grant of 15,000 shares of common stock for the quarter ended December 31, 2024 that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001493152-24-048365 · ownership.xml · derivative · entry 3

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,592

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs.

F5 · kind: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs.

F5 · price: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs.

F5 · derivative.exercise_date: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs.

F5 · derivative.expiration_date: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs.

F5 · derivative.underlying_shares: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs.

F4 · balance_after: The securities reported as acquired herein were granted to the Reporting Person by the Issuer in lieu of any other awards previously approved by the Issuer since the beginning of the fourth quarter of the Company's 2023 fiscal year, but were never issued by the Issuer, as an annual award grant to the Reporting Person in connection with the Reporting Person's service on the Issuer's Board of Directors for 2024 and a partial annual award grant for the Reporting Person's service on the Issuer's Board of Directors for the last quarter of 2023.

SEC source: 0001493152-24-048365 · ownership.xml · nonDerivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,793

F3 · kind: Represents a grant of restricted shares of Common Stock issued under the Plan which fully vested on the date of grant (the "Stock Award").

F3 · price: Represents a grant of restricted shares of Common Stock issued under the Plan which fully vested on the date of grant (the "Stock Award").

F2 · balance_after: The securities reported herein have been adjusted for the Company's one-for-eight reverse stock split effected on September 15, 2023.

F4 · balance_after: The securities reported as acquired herein were granted to the Reporting Person by the Issuer in lieu of any other awards previously approved by the Issuer since the beginning of the fourth quarter of the Company's 2023 fiscal year, but were never issued by the Issuer, as an annual award grant to the Reporting Person in connection with the Reporting Person's service on the Issuer's Board of Directors for 2024 and a partial annual award grant for the Reporting Person's service on the Issuer's Board of Directors for the last quarter of 2023.

SEC source: 0001493152-24-048365 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,405

F1 · kind: Represents a forfeiture of restricted shares of common stock (the "Forfeited Shares"), par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the AYRO, Inc. Long-Term Incentive Plan (as amended, the "Plan") in connection with the Reporting Person's service on the Issuer's Board of Directors that vested, but were not issued to the Reporting Person, on November 1, 2023. The Reporting Person received the Director Equity Awards (as defined herein), among other reasons as described herein, in lieu of such Forfeited Shares.

F1 · price: Represents a forfeiture of restricted shares of common stock (the "Forfeited Shares"), par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the AYRO, Inc. Long-Term Incentive Plan (as amended, the "Plan") in connection with the Reporting Person's service on the Issuer's Board of Directors that vested, but were not issued to the Reporting Person, on November 1, 2023. The Reporting Person received the Director Equity Awards (as defined herein), among other reasons as described herein, in lieu of such Forfeited Shares.

F2 · balance_after: The securities reported herein have been adjusted for the Company's one-for-eight reverse stock split effected on September 15, 2023.

SEC source: 0001493152-24-040938 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,413

F1 · price: Reflects the grant of 15,000 shares of common stock for the quarter ended September 30, 2024 that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001493152-24-027846 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,413

F1 · price: Reflects the grant of 15,000 shares of common stock for the quarter ended June 30, 2024 that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001493152-24-024970 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,413

F1 · price: Reflects the grant of 10,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001683168-24-004917 · ownership.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,009

Underlying: Common Stock · 38,009 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker. This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker.

SEC source: 0001493152-24-007552 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,413

F1 · price: Reflects the grant of 10,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001104659-23-129252 · tm2333705-2_4seq1.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-12-21

F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date.

SEC source: 0001683168-23-008433 · ownership.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,248

Underlying: Common Stock · 61,248 shares

Expires 2033-11-20

SEC source: 0001493152-23-041682 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,413

F1 · price: Reflects the grant of 10,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001415889-23-014441 · form4-10192023_081033.xml · nonDerivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · PRIOR DIRECTOR

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,575

F2 · price: Represents shares of Restricted Stock issued in connection with the Reporting Person's resignation from the Issuer's Board of Directors.

SEC source: 0001415889-23-014441 · form4-10192023_081033.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · PRIOR DIRECTOR

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,968

F1 · price: Represents shares of Restricted Stock (the "Shares") issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended September 30, 2023. The number of Shares was calculated based on the amount due the Reporting Person at the end of the quarter, or $15,125, divided by the closing price of the Company's Common Stock on such date. 30% of the Shares were vested as of the date of the grant, with the remainder vesting ratably in eight monthly tranches beginning November 1, 2023.

SEC source: 0001493152-23-026687 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 175,399

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8100 to $0.8450, inclusive. The reporting person undertakes to provide to AYRO, Inc., any security holder of AYRO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Represents a broker-assisted sale of shares subject to a 10b5(1) trading plan adopted by the reporting person on February 16, 2023 to pay taxes upon the vesting of an award.

SEC source: 0001493152-23-026292 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,413

F1 · price: Reflects the grant of 10,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001415889-23-010973 · form4-07102023_050752.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,885

F1 · price: Represents shares of Restricted Stock (the "Shares") issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended June 30, 2023. The number of Shares was calculated based on the amount due the Reporting Person at the end of the quarter, or $15,125, divided by the closing price of the Company's Common Stock on such date. 30% of the Shares were vested as of the date of the grant, with the remainder vesting ratably in eight monthly tranches beginning August 1, 2023.

SEC source: 0001493152-23-019080 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,413

F1 · ownership.direct: Reflects the grant of 6,413 shares of common stock to the reporting person for the November 3, 2022 to December 31, 2022 period of time that the reporting person served on the issuer's Board of Directors (the "Board"). On May 16, 2023, the Board modified the issuer's Director Compensation Policy upon the recommendation from the Board's Compensation Committee to allow for pro-rata issuances of stock to members of the Board for serving as a Board member for a portion of a quarter. The pro rata grant, however, is not issued to new members of the Board until after the completion of the new member's first complete quarter of service. The reporting person completed their first complete quarter of service on the Board on March 31, 2023.

SEC source: 0001493152-23-015693 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 182,673

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4700 to $0.5001, inclusive. The reporting person undertakes to provide to AYRO, Inc., any security holder of AYRO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Represents a broker-assisted sale of shares subject to a 10b5(1) trading plan adopted by the reporting person on February 16, 2023 to pay taxes upon the vesting of an award.

SEC source: 0001104659-23-053225 · tm2313909-2_4seq1.xml · derivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-053225 · tm2313909-2_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001493152-23-012310 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

F1 · price: Reflects the grant of 10,000 shares of common stock that members of the issuer's Board of Directors (the "Board") receive quarterly as part of their annual compensation for Board service.

SEC source: 0001104659-23-044713 · tm2312600-4_4seq1.xml · derivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2033-04-10

F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date.

SEC source: 0001415889-23-006213 · form4-04052023_020430.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,525

F1 · price: Represents shares of Restricted Stock (the "Shares") issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended March 31, 2023. The number of shares was calculated based on the amount due the Reporting Person at the end of the quarter, or $15,125, divided by the closing price of the Company's Common Stock on such date. 30% of the Shares were vested as of the date of the grant, with the remainder vesting ratably in eight monthly tranches beginning May 1, 2023.

SEC source: 0001415889-23-004523 · form4-03082023_110332.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,731

F1 · price: Represents shares of Restricted Stock (the "Shares") issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended December 31, 2022. The number of shares was calculated based on the amount due the Reporting Person at the end of the quarter, or $15,125, divided by the closing price of the Company's Common Stock on such date. 50% of the Shares were vested as of the date of the grant, with the remainder vesting ratably in five monthly tranches beginning April 1, 2023.

SEC source: 0001493152-23-003584 · ownership.xml · nonDerivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,483

F2 · shares: Shares will vest in four equal installments on each quarterly anniversary of the Grant Date, provided that Mr. Walker is employed by or providing services to the Company through the applicable vesting date and subject to the terms and conditions of the AYRO, Inc. Long-Term Incentive Plan.

SEC source: 0001493152-23-003584 · ownership.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,816

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7000 to $0.7446, inclusive. The reporting person undertakes to provide to AYRO, Inc., any security holder of AYRO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Represents a broker-assisted sale of shares subject to a 10b5(1) trading plan adopted by the reporting person on August 22, 2022 to pay taxes upon the vesting of an award.

SEC source: 0001104659-23-006547 · tm234334-4_4seq1.xml · derivative · entry 2

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

SEC source: 0001104659-23-006547 · tm234334-4_4seq1.xml · nonDerivative · entry 1

WALKER WAYNE REMELL · CIK 0001428761 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.

F2 · price: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.

F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.